Pfizer to Close Manufacturing Plant in Puerto Rico by 2017 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer to Close Manufacturing Plant in Puerto Rico by 2017


Pfizer will close one of its three manufacturing facilities in Puerto Rico by the end of 2017, the company announced in a Nov. 20, 2013 press release. Pfizer has determined that facility consolidation is necessary because of excess capacity in its manufacturing network created by the achievement of greater efficiencies in manufacturing processes and by changing global demand, which has resulted from the loss of patent exclusivity.

“The decision to exit Barceloneta came after a comprehensive review of the company’s global manufacturing network as it exists today and what will be needed in the future to ensure Pfizer’s success in the years ahead,” said John Kelly, vice-president, Strategy and Transitioning Sites, in the press release.  “The reality is that Pfizer’s manufacturing network has more capacity than it needs and to remain competitive the company must match its manufacturing capacity with the future needs of the business.  In spite of this change, Puerto Rico remains an important location for Pfizer with major operations in Guayama and Vega Baja.”

Barceloneta produces APIs as well as several drug products.  Pfizer will move manufacturing of the products that Barceloneta currently produces to other plants within its global network, including Vega Baja, Puerto Rico; Ringaskiddy and Newbridge in Ireland; and Tuas, Singapore.

Pfizer employs close to 700 people at Barceloneta and close to 2700 people in Puerto Rico overall. Manufacturing facilities are located in Barceloneta, Guayama, and Vega Baja, and commercial offices located in San Juan. Pfizer’s manufacturing facilities at Vega Baja and Guayama in Puerto Rico are not impacted by this decision.  Due to the complexity of the transition, Pfizer does not expect to see any significant impact on headcount before late 2014, and noted that it would be premature at this time to determine the effect on employment as the company explores strategic options for Barceloneta.  

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here